Connection

Richard Silver to Antirheumatic Agents

This is a "connection" page, showing publications Richard Silver has written about Antirheumatic Agents.
Connection Strength

0.387
  1. Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology (Oxford). 2022 10 06; 61(10):4155-4162.
    View in: PubMed
    Score: 0.202
  2. Outcome measures in the lung. Rheumatology (Oxford). 2008 Oct; 47 Suppl 5:v48-50.
    View in: PubMed
    Score: 0.077
  3. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
    View in: PubMed
    Score: 0.069
  4. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. Arthritis Rheumatol. 2019 02; 71(2):182-195.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.